PON1 status in haemodialysis patients and the impact of hepatitis C infection

Clinical Biochemistry

Volumn 40, Issue 9-10, 2007, Pages 609-614

  Horoz, Mehmet ^a   Aslan, Mehmet ^a   Selek, Sahbettin ^a   Koylu, Ahmet O ^a   Bolukbas, Cengiz ^a   Bolukbas, Filiz F ^a   Celik, Hakim ^a   Erel, Ozcan ^a  

^a HARRAN UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Arylesterase; Atherosclerosis; Chronic renal failure; Haemodialysis; Hepatitis C; Lipid hydroperoxide; Paraoxonase

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; ARYLESTERASE; LIPID HYDROPEROXIDE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL STUDY; CONTROLLED STUDY; DEMOGRAPHY; ENZYME ACTIVITY; FEMALE; GENETIC POLYMORPHISM; HEMODIALYSIS; HEPATITIS C; HUMAN; MALE; OXIDATION; PRIORITY JOURNAL; SPECTROPHOTOMETRY; VIRUS INFECTION;

ADULT; ARYLDIALKYLPHOSPHATASE; CARBOXYLIC ESTER HYDROLASES; FEMALE; HEPATITIS C, CHRONIC; HUMANS; KIDNEY FAILURE, CHRONIC; LIPID PEROXIDES; MALE; MIDDLE AGED; RENAL DIALYSIS;

EID: 34249673500     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2007.01.019     Document Type: Article

References (37)

1. Costa L.G., Li W.F., Richter R.J., Shih D.M., Lusis A., and Furlong C.E. The role of paraoxonase (PON1) in the detoxification of organophosphates and its human polymorphism. Chem.-Biol. Interact. 119-120 (1999) 429-438
2. Canales A., and Sanchez-Muniz F.J. Paraoxanase, something more than an enzyme?. Med. Clin. (Barc) 121 (2003) 537-548
3. Ayub A., Mackness M.I., Arrol S., Mackness B., Patel J., and Durrington P.N. Serum paraoxonase after myocardial infarction. Arterioscler. Thromb. Vasc. Biol. 19 (1999) 330-335
4. Humbert R., Adler D.A., Disteche C.M., Hassett C., Omiecinski C.J., and Furlong C.E. The molecular basis of the human serum paraoxonase activity polymorphism. Nat. Genet. 3 (1993) 73-76
5. Mackness B., Durrington P.N., and Mackness M.I. Human serum paraoxonase. Gen. Pharmacol. 31 (1998) 329-336
6. Nevin D.N., Zambon A., Furlong C.E., Richter R.J., Humbert R., Hokanson J.E., et al. Paraoxonase genotypes, lipoprotein lipase activity, and HDL. Arterioscler. Thromb. Vasc. Biol. 16 (1996) 1243-1249
7. Obata T., Ito T., Yonemura A., Ayaori M., Nakamura H., and Ohsuzu F. R192Q paraoxonase gene variant is associated with a change in HDL-cholesterol level during dietary caloric restriction in nondiabetic healthy males. J. Atheroscler. Thromb. 10 (2003) 57-62
8. Van Himbergen T.M., Roest M., de Graaf J., Jansen E.H.J.M., Hattori H., Kastelein J.J.P., et al. Indications that paraoxonase-1 contributes to plasma high density lipoprotein levels in familial hypercholesterolemia. J. Lipid Res. 46 (2005) 445-451
9. Ng C.J., Shih D.M., Hama S.Y., Villa N., Navab M., and Reddy S.T. The paraoxonase gene family and atherosclerosis. Free Radical Biol. Med. 38 (2005) 153-163
10. Paragh G., Seres I., Balogh Z., Varga Z., Karpati I., Matyus J., et al. The serum paraoxonase activity in patients with chronic renal failure and hyperlipidemia. Nephron 80 (1998) 166-170
11. Himmelfarb J., McMonagle E., and McMenamin E. Plasma protein thiol oxidation and carbonyl formation in chronic renal failure. Kidney Int. 58 (2000) 2571-2578
12. Miyata T., Fu M.X., Kurokawa K., Van Ypersele de Strihou C., Thorpe S.R., and Baynes J.W. Autoxidation products of both carbohydrates and lipids are increased in uremic plasma: is there oxidative stress in uremia?. Kidney Int. 54 (1998) 1290-1295
13. Zoccali C., Mallamaci F., and Tripepi G. AGEs and carbonyl stress: potential pathogenetic factors of long-term uraemic complications. Nephrol. Dial. Transplant. 15 (2000) 7-11
14. Miyata T., Sugiyama S., Saito A., and Kurokawa K. Reactive carbonyl compounds related uremic toxicity ("carbonyl stress"). Kidney Int. 59 (2001) 25-31
15. Jackson P., Loughrey C.M., Lightbody J.H., McNamee P.T., and Young I.S. Effect of haemodialysis on total antioxidant capacity and serum antioxidants in patients with chronic renal failure. Clin. Chem. 41 (1995) 1135-1138
16. Schiavon R., Defanti E., Giavarina D., Biasioli S., Cavalcanti G., and Guidi G. Serum paraoxonase activity is decreased in uremic patients. Clin. Chim. Acta 247 (1996) 71-80
17. Juretic D., Tadijanovic M., Rekic B., Simeon-Rudolf V., Reiner E., and Baricic M. Serum paraoxonase activities in hemodialyzed uremic patients: cohort study. Croat. Med. J. 42 (2001) 146-150
18. Dirican M., Akça R., Sarandol E., and Dilek K. Serum paraoxonase activity in uremic predialysis and haemodialysis patients. J. Nephrol. 17 (2004) 813-818
19. Fabrizi F., Lunghi G., Raffaele L., Guarnori I., Bacchini G., Corti M., et al. Serologic survey for control of hepatitis C in haemodialysis patients: third-generation assays and analysis of costs. Nephrol. Dial. Transplant. 12 (1997) 298-303
20. Kilic S.S., Aydin S., Kilic N., Erman F., Aydin S., and Celik I. Serum arylesterase and paraoxonase activity in patients with chronic hepatitis. World J. Gastroenterol. 11 (2005) 7351-7354
21. Ferre N., Marsillach J., Camps J., Mackness B., Mackness M., Riu F., et al. Paraoxonase-1 is associated with oxidative stress, fibrosis and FAS expression in chronic liver diseases. J. Hepatol. 45 (2006) 51-59
22. Ferre N., Camps J., Prats E., Vilella E., Paul A., Figuera L., et al. Serum paraoxonase activity: a new additional test for the improved evaluation of chronic liver damage. Clin. Chem. 48 (2002) 261-268
23. Ferre N., Marsillach J., Camps J., Rull A., Coll B., Tous M., et al. Genetic association of paraoxonase-1 polymorphisms and chronic hepatitis C virus infection. Clin. Chim. Acta 361 (2005) 206-210
24. Ishizaka N., Ishizaka Y., Takahashi E., Toda Ei E., Hashimoto H., Ohno M., et al. Increased prevalence of carotid atherosclerosis in hepatitis B virus carriers. Circulation 105 (2002) 1028-1030
25. Ishizaka N., Ishizaka Y., Takahashi E., Tooda E., Hashimoto H., Nagai R., et al. Association between hepatitis C virus seropositivity, carotid-artery plaque, and intima-media thickening. Lancet 359 (2002) 133-135
26. Volzke H., Schwahn C., Wolff B., Mentel R., Robinson D.M., Kleine V., et al. Hepatitis B and C virus infection and the risk of atherosclerosis in a general population. Atherosclerosis 174 (2004) 99-103
27. Bilora F., Rinaldi R., Boccioletti V., Petrobelli F., and Girolami A. Chronic viral hepatitis: a prospective factor against atherosclerosis. A study with echo-color Doppler of the carotid and femoral arteries and the abdominal aorta. Gastroenterol. Clin. Biol. 26 (2002) 1001-1004
28. Eckerson H.W., Wyte M.C., and La Du B.N. The human serum paraoxonase/arylesterase polymorphism. Am. J. Hum. Genet. 35 (1983) 1126-1138
29. Haagen L., and Brock A. A new automated method for phenotyping arylesterase (E.C.3.1.1.2.) based upon inhibition of enzymatic hydrolysis of 4-nitrophenyl acetate by phenyl acetate. Eur. J. Clin. Chem. Clim. Biochem. 30 (1992) 391-395
30. Nourooz Zadeh J. Ferrous ion oxidation in presence of xylenol orange for detection of lipid hydroperoxides in plasma. Methods Enzymol. 300 (1999) 58-62
31. Aviram M., Rosenblat M., Billecke S., Erogul J., Sorenson R., Bisgaier C.L., et al. Human serum paraoxonase (PON1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radical Biol. Med. 26 (1999) 892-904
32. Koken T., Serteser M., Kahraman A., and Gokce C. Oxidative stress markers in hepatitis C infected haemodialysis patients. J. Nephrol. 15 (2002) 302-307
33. Nascimento M.M., Suliman M.E., Bruchfeld A., Hayashi S.Y., Manfro R.C., Qureshi A.R., et al. The influence of hepatitis C and iron replacement therapy on plasma pentosidine levels in haemodialysis patients. Nephrol. Dial. Transplant. 19 (2004) 3112-3116
34. Kato A., Odamaki M., Nakamura H., Yodoi J., and Hishida A. Elevation of blood thioredoxin in haemodialysis patients with hepatitis C virus infection. Kidney Int. 63 (2003) 2262-2268
35. Horoz M., Bolukbas C., Bolukbas F.F., Aslan M., Koylu A.O., Selek S., et al. Oxidative stress in hepatitis C infected end-stage renal disease subjects. BMC Infect. Dis. 6 (2006) 114
36. Fabrizi F., Martin P., Dixit V., Brezina M., Cole M.J., Vinson S., et al. Biological dynamics of viral load in haemodialysis patients with hepatitis C virus. Am. J. Kidney Dis. 35 (2000) 122-129
37. Martin J., de Sequera P., Quiroga J.A., Rico M., Fernandez M., Arocena C., et al. Role of haemodialysis and hepatitis c virus infection in spontaneous and induced cytokine production of patients with chronic renal disease. Cytokine 12 (2000) 1248-1252